Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.

Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...

Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and ...

Eli Lilly ( LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound.

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...